GlassScriptPhysician profile
Anthony J Marion
NPI 1609313048
$7,859.05
in general payments reported to CMS, 2019-2025
26 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,311 · 2022: $1,895 · 2023: $1,503 · 2024: $1,339 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,652.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,556.21 | 2021-2025 | |
| Incyte Corporation | $1,026.99 | 2022-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $781.55 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $777.00 | 2021-2024 | Ilumya |
| Genzyme Corporation | $744.61 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $516.71 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $491.13 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $361.20 | 2021-2025 | Otezla, Otezla |
| Organon LLC | $281.95 | 2025 | Vtama, Nexplanon |
| Dermavant Sciences, INC. | $269.23 | 2023-2024 | Vtama |
| Journey Medical Corporation | $141.63 | 2022-2023 | |
| Almirall LLC | $117.82 | 2021-2025 | Seysara |
| Regeneron Healthcare Solutions, INC. | $108.36 | 2023-2024 | Dupixent, Libtayo |
| Leo Pharma INC. | $93.42 | 2023-2024 | Adbry |
| Arcutis Biotherapeutics, INC. | $89.35 | 2023-2024 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $85.88 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.25 | 2021-2024 | Cabtreo, Jublia, Arazlo |
| Galderma Laboratories, L.P. | $81.82 | 2023-2025 | Nemluvio, Aklief |
| Ucb, INC. | $77.84 | 2025 | Bimzelx |
| Epi Health, LLC | $54.35 | 2021-2022 | |
| Advanced Respiratory, INC | $26.77 | 2021 | |
| Mayne Pharma Commercial LLC | $26.67 | 2022 | |
| Vyne Pharmaceuticals INC. | $17.72 | 2021 | |
| Pfizer INC. | $16.22 | 2024 | |
| Krystal Biotech INC | $15.64 | 2025 | Vyjuvek |
| Jazz Pharmaceuticals INC. | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Marion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.